API
< Back to all clusters
[HEALTH] · Saudi Arabia, United Kingdom · 5 sources

started · updated

Saudi FDA signs memorandum with UK MHRA to accelerate medical innovation

The Saudi Food and Drug Authority (SFDA) has signed a memorandum of understanding with the UK Medicines and Healthcare products Regulatory Agency (MHRA) to enhance the evaluation of innovative treatments and speed up patient access to medicines.

The agreement was signed in London during the DIA-MHRA Global Summit on November 16 and 17, 2026. The signatories included SFDA CEO Dr. Hisham bin Saad Al-Jadai and MHRA CEO Lawrence Talon, in the presence of MHRA Chairman Professor Sir Anthony Harnden.

Key areas of cooperation include the assessment of treatments for rare diseases, advanced therapies, and biotechnology products. The partnership will also focus on utilizing artificial intelligence, modeling, and computer simulations in clinical trials. Additionally, both agencies will exchange expertise regarding medical product registration, good manufacturing practices, quality systems, and supply chain monitoring to ensure safety in both markets. This collaboration aligns with Saudi Vision 2030 and the National Biotechnology Strategy to bolster national capabilities and innovation.

Entities

Hisham bin Saad Al-Jadai · Hisham bin Saad Al-Jadaie · Lawrence Talon · London · Medicines and Healthcare products Regulatory Agency · Saudi Food and Drug Authority